Grow Your Vision

Welcome visitors to your site with a short, engaging introduction.

Double click to edit and add your own text.

Highlights from

SCCT 2026

News and Updates

Should We Screen Asymptomatic Patients with Coronary CT?

Coronary CT has become one of the most powerful imaging technologies for cardiovascular risk assessment. However, an important clinical question remains: Should Coronary CT Angiography (CCTA) be used routinely to screen asymptomatic individuals, or does Coronary Artery Calcium (CAC) scanning already provide sufficient information for preventive care? This presentation reviews the current evidence comparing CAC scoring and CCTA in primary prevention, examining their predictive

Slide Presentations

Jul 191 min read

Two HeartLung.AI Studies Show Routine Chest CT Can Assess Cardiac Risk Comparably to Dedicated Cardiac CT and Echocardiography

Complementary MESA analyses validate AI-derived cardiac chamber volumetry from non-gated, non-contrast CT for opportunistic heart failure and atrial fibrillation risk assessment HOUSTON - July 16, 2026 - HeartLung.AI announced the acceptance of two complementary studies in the American Journal of Preventive Cardiology demonstrating that artificial intelligence can extract clinically meaningful cardiac chamber measurements from routine non-gated, non-contrast chest CT and asse

Jul 164 min read

Vision 2030: Preventive Imaging Agentic AI

Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial Vision 2030 presents HeartLung.AI’s long-term vision for transforming medical imaging into a comprehensive, AI-powered preventive healthcare ecosystem. Rather than generating a diagnostic report alone, the platform is designed to convert a single medical image into a personalized prevention strategy that follows patients throughout their lives. The proposed Preventive Imaging Agentic AI framework integrates multiple in

Slide Presentations

Jul 151 min read

LDCT Mega Trial — Preventive Imaging Agentic AI vs. Usual Care

Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual Care The LDCT Mega Trial is an ambitious vision for one of the largest prospective clinical studies ever proposed in artificial intelligence, designed to evaluate whether an Agentic AI-powered preventive imaging ecosystem can improve long-term health outcomes compared with conventional medical care. The proposed randomized trial plans to enroll 100,000 participants across 250 cl

Slide Presentations

Jul 151 min read

AI-CVD: AI-Powered Cardiovascular Risk Assessment from CAC and Chest CT

Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual CareLIFEMAP Research Group AI-CVD is an advanced artificial intelligence platform that transforms routine coronary artery calcium (CAC) and chest CT scans into comprehensive cardiovascular risk assessments by extracting a wide range of imaging biomarkers from a single examination. Rather than relying solely on traditional clinical risk factors, AI-CVD analyzes multiple cardiome

Slide Presentations

Jul 151 min read

AI-CAC: Coronary Plaque Analysis from Non-Contrast CT

AI-CAC introduces a novel artificial intelligence approach for coronary plaque analysis using non-contrast cardiac CT (CAC) scans, offering the potential to extract plaque characteristics traditionally obtainable only from contrast-enhanced coronary CT angiography (CCTA). Conventional CCTA provides excellent visualization of coronary anatomy but requires intravenous contrast administration and is affected by scanner-, software-, and observer-related variability. AI-CAC addres

Slide Presentations

Jul 151 min read

2 3 4 5